BACKGROUND: Leukocyte depletion at the time of transplantation with alemtuzumab (Campath-1H) has been demonstrated to be a potential strategy for reducing long-term exposure to immunosuppressive drugs. Although the impact of alemtuzumab treatment on the immune system has been explored, the effects of long-term immunosuppressive therapy in alemtuzumab-treated patients still need to be elucidated. METHODS: T-regulatory cells and Th1/Th17 responses were assessed by flow cytometry and real-time p...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Th17 cells in alemtuzumab-treated patients: the effect of long-term maintenance immunosuppressive therapy.
If you are the owner of this record, you can report an update to it here: Report update to this record